Therapy (HCV)
"Daily Interferon Regimen for Chronic Hepatitis C - A Prospective Randomised Study."
Published in Hepatitis Weekly, September 6th, 1999
According to the authors' abstract of an article published in Clinical Drug Investigation, "Objective: To compare the safety and efficacy of two regimens of lymphoblastoid interferon, 3MU daily for 12 months vs. 6MU three times weekly for 12 months, for the treatment of patients with chronic hepatitis C. Design: This was a prospective, randomised, nonblind study. Setting: The study was conducted in outpatients attending the University Hospital in Pavia, Italy, between 1997 and 1998. Patients: 100 treatment-naive outpatients with chronic hepatitis C genotype Ib participated in the study. Main Outcome Measures: We measured serum hepatitis C...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
Source: Hepatitis Weekly (1999-09-06)
More Articles from Hepatitis Weekly
- Interferon Therapy (HBV)
Lengthened IFN Therapy Improves HBV Outcome - Coinfection (HCV/HBV)
HCV Infection Alters HBV Progression - Disease Associations
HBV Infection Could Be Linked to Aplastic Anemia - Epidemiology (TTV/HCV)
TTV Incidence Independent of HCV in Japan - Interferon Therapy (HCV)
IFN-(beta) May Be Wrong Choice in HCV with Myasthenia Gravis - Interferon Therapy (HCV)
Serum Gamma-GT/ALT May Show IFN Response - More from this issue of Hepatitis Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
